Author

J L Hu

Observed names: Jhen-You Hu, Jiaqian Hu

Institutions: Taichung City Government, Nanjing University

Observed institutions: Shanxi University, Shanghai Jiao Tong University, Jiangsu Provincial Center for Disease Control and Prevention, Shanghai First People's Hospital, Taichung City Government, Nanjing University

ORCID: 0009-0000-4631-6711

Observed ORCID: 0009-0000-4631-6711

OpenAlex ID: A5018989202

Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody

2024 · Mengmeng Ji, Jiaqian Hu, et al. · EMBO Molecular Medicine · 20

[Efficacy and safety of low-intensity pulsed ultrasound at different intervals by mechanical force in treating erectile dysfunction: a preliminary study].

2020 · S J Xia, H R Chen, et al. · PubMed · 9

A rationally designed cocktail of nanobodies elicited by heterologous vaccination confers protection against SFTSV in preclinical models

2025 · Xilin Wu, Linjing Zhu, et al. · Science Translational Medicine · 6

Olfactory and Gustatory Disturbances as Early Indicators of Lung Cancer in Patients with Sleep Disorders: A Retrospective Cohort Study from the TriNetX US Collaborative Networks

2025 · Ru-Yin Tsai, Chi-Chung Ho, et al. · International Journal of Medical Sciences · 1

[Construction of urban scale-free network model and its epidemiological significance in the prevention and control of COVID-19].

2020 · W Y Song, Z X Ding, et al. · PubMed · 1

Updated meta‑analysis on the therapeutic effects of botanical extract interventions for chronic lower back pain

2025 · Ru-Yin Tsai, Chin-Chang Chen, et al. · Experimental and Therapeutic Medicine

[Application of IgG antibody combination of wild strain and epidemic strain of COVID-19 in identifying epidemic Omicron BA.5 strain infection].

2024 · J J Chu, H Tian, et al. · PubMed

[Analysis on the secondary attack rates of SARS-CoV-2 Omicron variant and the associated factors].

2023 · Q X Shang, K Xu, et al. · PubMed

[Immunogenicity and safety of a booster vaccination with an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in adults aged 18 to 59 years].

2022 · H X Pan, B Y Huang, et al. · PubMed

Works count: 9

Citation count: 37

H-index: 3

I10-index: 1